← All trials
NCT03602079
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 16, 2018
- Primary completion
- Oct 31, 2020
- Completion date
- May 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 82
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Klus Pharma Inc.Lead sponsor
- University of Texas at HoustonStudy chair
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Bile Duct Neoplasms
- Urinary Bladder Neoplasms
- Breast Neoplasms
- Carcinoma, Renal Cell
- Uterine Cervical Neoplasms
- Colonic Neoplasms
- Hamartoma
- Head and Neck Neoplasms
- Laryngeal Neoplasms
- Liver Neoplasms
- Lung Neoplasms
- Mouth Neoplasms
- Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Prostatic Neoplasms
- Rectal Neoplasms
- Salivary Gland Neoplasms
- Skin Neoplasms
- Stomach Neoplasms
- Tongue Neoplasms
- Tonsillar Neoplasms
- Urologic Neoplasms
- Colorectal Neoplasms
- Carcinoma, Mucoepidermoid
- Cholangiocarcinoma
- Genes, erbB-2
- Rare Diseases
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.